




# Enhancing Access to Prescription Drug Monitoring Programs

A national effort to reduce prescription  
drug abuse and overdose through  
technology and policy

# Today's Agenda



## Overview



**Work Groups**



**Pilots**

# The Team



Kate Tipping, ONC, [Kate.Tipping@hhs.gov](mailto:Kate.Tipping@hhs.gov)



Nick Reuter, SAMHSA, [Nicholas.Reuter@samhsa.hhs.gov](mailto:Nicholas.Reuter@samhsa.hhs.gov)

Jinhee Lee, SAMHSA, [Jinhee.Lee@samhsa.hhs.gov](mailto:Jinhee.Lee@samhsa.hhs.gov)



Chris Jones, CDC, [cjones@cdc.gov](mailto:cjones@cdc.gov)



Cecelia Spitznas, ONDCP,  
[Cecelia M Spitznas@ondcp.eop.gov](mailto:Cecelia_M_Spitznas@ondcp.eop.gov)



Lisa Tutterow, MITRE, [ltutterow@mitre.org](mailto:ltutterow@mitre.org)

Jeffrey Hammer, MITRE, [jmhammer@mitre.org](mailto:jmhammer@mitre.org)



# OVERVIEW




# The Problem



- The Centers for Disease Control and Prevention (CDC) declared that deaths from prescription painkillers now **outnumber deaths from heroin and cocaine combined**
- In 2010, U.S. pharmacies dispensed **69 tons of oxycodone** and **42 tons of hydrocodone**—enough for each American to receive 40 Percocet and 24 Vicodin

Figure 1. Motor vehicle traffic, poisoning, and drug poisoning death rates: United States, 1980–2008



NOTE: In 1999, the *International Classification of Diseases, Tenth Revision (ICD-10)* replaced the previous revision of the ICD (ICD-9). This resulted in approximately 5% fewer deaths being classified as motor-vehicle traffic-related deaths and 2% more deaths being classified as poisoning-related deaths. Therefore, death rates for 1998 and earlier are not directly comparable with those computed after 1998. Access data table for Figure 1 at [http://www.cdc.gov/nchs/data/databriefs/db81\\_tables.pdf#1](http://www.cdc.gov/nchs/data/databriefs/db81_tables.pdf#1).  
SOURCE: CDC/NCHS, National Vital Statistics System.



- PDMPs contain useful information
  - Identify patients who are potentially **abusing or diverting** prescription drugs
  - Inform **clinical decisions** regarding controlled substances
- The issue is how to make this information more available to three key groups of clinical decision makers:



# The Story So Far



**White House  
Roundtable on  
Health IT  
& Prescription  
Drug Abuse  
June 3, 2011**

**Federal & State Partners**

**State Participants**

**Stakeholders**

Substance Abuse & Mental Health Services Administration

**Organizations**


## Action Plan

**ACTION PLAN FOR IMPROVING ACCESS TO  
PRESCRIPTION DRUG MONITORING  
PROGRAMS THROUGH HEALTH INFORMATION  
TECHNOLOGY**

Presented to  
The Behavioral Health Coordinating Committee,  
Department of Health and Human Services  
through  
The Pharmaceutical Abuse Subcommittee  
by the  
Prescription Drug Abuse and  
Health Information Technology Work Group

JUNE 30, 2011

# Project Structure and Objectives



***Reduce prescription drug misuse and overdose in the United States***

# Desired Results



- Recommendations on policies/law around the use of PDMP data by providers or dispensers
- Feasible, vendor-independent, technical solutions that are scalable and useable by states
- New levels of cooperation among health IT sectors around PDMP
- Increased practitioner use of PDMPs
- Reduced prescription drug misuse and overdose



# WORK GROUPS



# Work Groups



- Convened to address issues impacting the access and use of PDMP data
- Explored the legal, technological, and operational aspects of the PDMP data and user landscapes
- Developed specific recommendations aimed at improving timely access to PDMP information
- Identified additional areas of exploration



# Work Group Engagement




# Work Groups



Number/Name	Purpose
<b>1: Data Content and Vocabulary</b>	To determine the data content and vocabulary necessary to support data exchange between PDMP and recipients.
<b>2: Information Usability and Presentation</b>	To determine how PDMP information will be presented in the user interfaces for pharmacy systems and provider and ED Electronic Health Records (EHR) to maximize the value of this data for the treatment and dispensing decision-making processes.
<b>3: Transport and Architecture</b>	To explore and develop the technical specifications for data transmission (e.g., REST, SOAP, Direct) between PDMPs and a variety of recipient systems and intermediaries.
<b>4: Law and Policy</b>	To explore legal and policy issues in support of program objectives, including PDMP data access within various recipient settings, use of intermediaries to enable PDMP data exchange and specific Pilot Program scenarios in the context of specific state(s).
<b>5: Business Agreements for Intermediaries</b>	To analyze the current business environment relevant to the use of intermediaries (e.g., Switches, HIEs) to route transmissions between PDMPs and data recipients.




- Full write-up of following slides
- Detailed recommendations and rationales
- Downloadable templates
- Will be posted on ONC website
- Currently in review process
  
- Today
  - Summary of findings
  - Preliminary recommendations



# Findings of the Work Groups



- PDMPs contain useful information
- **Five Impediments** may hinder physicians and pharmacists from accessing or using this information



The Work Groups developed **recommendations** to address each of these impediments

Recognized **diverse nature** of PDMP's laws, technology, etc.



## Overview

PDMPs are not used as much as desired because of **issues with awareness and system registration**

### Specific Impediments

- Prescribers and dispensers are unsure of how PDMP data may support the care they provide
- Lack awareness and education of the value of this data
- Concern over increased liability
- Lack of trust in PDMP data because of data currency



	Recommendations
1A	Streamline the <b>registration process</b> <ul style="list-style-type: none"><li>• Review current registration procedures</li><li>• Institute automatic and mandatory registration</li></ul>
1B	Provide <b>increased protection</b> from civil and criminal liability for authorized users
1C	<b>Increase awareness</b> on value and use of PDMP data at the point of care <ul style="list-style-type: none"><li>• Implement awareness campaigns and education programs</li></ul>
1D	Consider more <b>real-time transmission</b> of dispensed data to PDMPs <ul style="list-style-type: none"><li>• Implement more frequent reporting of PDMP information</li><li>• Move toward real time reporting</li><li>• Increase electronic reporting</li></ul>



## Overview

Members of the care team supporting prescribers and dispensers often are **not permitted access** to PDMP systems

### Specific Impediment

- In 32 of the 42 states with operational PDMPs, both prescribers and dispensers may not delegate the authority to their staffs to access patients' controlled-substance drug histories



## Recommendation

2

- **Expand the pool** of authorized healthcare professionals permitted to access PDMP data
  - Their access can impact patient care
  - Support real-world clinical practices
- Grant these professionals the authority to **appoint delegates** who can access this data on their behalf
  - Would align with HIPAA
  - More easily expand the number of authorized users



## Overview

The use of standalone Web portals and unsolicited reports **do not adequately support clinical practices** and workflows

### Specific Impediments

- Prescribers /dispensers have limited time to access separate PDMP system
- Unsolicited alerts may go unnoticed
- Difficult to attach unsolicited alert to a patient in an EHR
- There currently is no standard for the specific data that must be included in all PDMP reports

# Lack of Workflow Support (cont.)



	Recommendations
3A	<b>Integrate access</b> to the PDMP Web portal in EHR and pharmacy systems
3B	Consider secure <b>electronic communication</b> of unsolicited alerts
3C	Send prescribers and dispensers an <b>alert or notification</b> when they receive an unsolicited report
3D	Allow <b>customizable patient-at-risk filters</b>
3E	Provide a variety of <b>mechanisms for PDMP access</b> at the point of care
3F	Define a <b>standard set of data</b> that should be available to support clinical decision making



## Overview

There is a **lack of system-level access and standards** among PDMPs, EHRs, and pharmacy systems.

### Specific Impediments

- Lack of standards for automated queries
- Lack of standards for automated unsolicited reporting
- No formal standards or specifications for sharing PDMP reports electronically
- Lack of interoperability between PDMPs and systems used by prescribers and dispensers

# Low Technical Maturity (cont.)



	Recommendations
4A	<p>Standardize and adopt a <b>data exchange standard</b></p> <ul style="list-style-type: none"><li>• Adopt the National Information Exchange Model (NIEM) Prescription Monitoring Program (PMP) specification for information exchange<ul style="list-style-type: none"><li>• The interstate hubs (RxCheck and PMPi) use the PMIX architecture which includes this</li></ul></li><li>• Formalize adoption as part of the NIEM Health Domain</li></ul>
4B	<p>Develop <b>system-level access</b> to PDMPs</p> <ul style="list-style-type: none"><li>• Define application programming interface (API)</li></ul>
4C	<p>Standardize three <b>PDMP interfaces</b> to improve interoperability</p>
4D	<p><b>Share and distribute</b> PDMP technical products</p> <ul style="list-style-type: none"><li>• Using the NIEM Health Domain</li></ul>



## Overview

The business and health IT landscape increasingly contains third-party intermediaries which currently **lack optimized business agreements** to adequately protect information

### Specific Impediment


- Configure appropriate legal agreements to enable PDMP data flow while protecting the privacy of patients entails considerable effort and expense

# Lack of Business Agreements (cont.)



## Recommendations

- 5
- Implement an **agreement framework** and model agreements to facilitate data sharing through intermediaries
  - The Agreement Framework should be built of the following components: Business Agreements, Business Associate Agreements and “State Boilerplate” Language





- From the Meeting Room to the Front Lines
- Efforts to connect PDMPs and health IT
- Envisioned pilots

***Stick Around***




# PILOTS



# Why Pilots?



- PDMPs today
  - primarily standalone systems
  - Separated from rest of health IT ecosystem
  - accessed via web portals
  - **Human-centric process**
- PDMPs tomorrow
  - Integrated with other health IT in the patient workflow
  - **Machine-centric process**





- Use **existing technologies** to facilitate exchange of information
- Leverage what is **in use today** for other purposes
- Open to **new approaches** to enhance access to PDMP data

# Pilot Types



<b>Technology Enabler</b>	<b>Community that Will be Making Decisions on PDMP Data</b>		
	<b>Providers</b>	<b>Emergency Departments</b>	<b>Pharmacies</b>
<b>Direct Messaging</b>	PDMP sends report to provider when patient exceeds state-defined threshold. Secure message sent to provider-specific EHR In-basket		
<b>Trigger</b>	<ul style="list-style-type: none"> <li>Scheduling of patient appointment</li> <li>Check-in of the patient</li> <li>Eligibility check</li> <li>eRx controlled substance prescription</li> </ul>	<ul style="list-style-type: none"> <li>Patient presents at ED</li> </ul>	<ul style="list-style-type: none"> <li>Prescription fill</li> <li>Receipt of electronic prescription</li> </ul>
<b>Intermediary</b>	<ul style="list-style-type: none"> <li>Health Information Exchange (HIE)</li> <li>Scoring system</li> </ul>	<ul style="list-style-type: none"> <li>HIE</li> <li>Centralized Care Management System</li> </ul>	<ul style="list-style-type: none"> <li>Switch</li> <li>HIE</li> </ul>



- NASCSA 2011
- Alliance for States with PMPs – Webinar
- Newsletter piece in FSMB, NASCSA, Alliance
- HIMSS12 conference with about 20 State HIEs
- HIMSS Quality Safety Measure
- 100+ One-on-one calls
- ONC State HIE eRx CoP
- Networking



- Goals
  - Extensible results
  - Vendor neutral solutions
  - Determine what works and doesn't work
- Types of Results



**Clinical**




**Technical**



**Legal**

# Emergency Department/Hub Pilot



- **Type**

- Emergency Department

- **Trigger**

- ADT
- Machine to machine call

- **Intermediary(s)**

- Interstate hub


- **Result**

- PDMP data stored in EMR patient record

- **Desired Outcomes**

- Increased use by ED staff
- Data available at right time
- More convenient access
- Better prescribing decisions

# Ambulatory/Intermediary Pilot



- **Type**

- Ambulatory

- **Trigger**

- Appointment
- Check-in (data refresh)

- **Intermediary**

- Analysis engine
- HIE

- **Result**

- Risk profile
- Link to full PDMP report and data analysis

- **Desired Outcomes**

- Data available at right time
- More convenient access
- Better prescribing decisions



- **Type**
  - Emergency Department
- **Trigger**
  - Physician Activated
  - Single Sign On (SSO) and Patient Context
- **Intermediary**
  - HIE

- **Result**
  - PDMP data returned to EMR in pop-up window
- **Desired Outcomes**
  - Feasibility of Single Sign On and Patient Context
  - Compare manual call vs. machine-to-machine call

# Pharmacy/Switch Pilot



- **Type**
  - Pharmacy
- **Trigger**
  - Rx fill request
  - Uses switch “eligibility check” message format
- **Intermediary**
  - Claims Switch

- **Result**
  - Binary Accept/Reject flag sent back to Pharmacy System (Reject = check PDMP)
- **Desired Outcomes**
  - Effectiveness of flag as at-risk filter
  - Lessons from using switch

# Next Steps




- Complete planning/contracting process
- Finish pilots in August
- Pursue non-pilot activities
- Final Report in September
- Continue outreach and communication

# Final Thought



## Overview



Work Groups

Pilots

